Chronic Limb Threatening Ischemia Pharma Commercialization Services Intraoperative Molecular Imaging Laparoscopic Surgery Smart Abdominal Binder Digital Health – Remote Patient Monitoring Protein Characterization Clinical Research Organization Senior Living

This report provides a review of revenue growth for public companies in FSI’s Life Science Tools and Diagnostics segments in 2022 as well as US investments and exits

This report highlights FSI's Peripheral Vascular (PV) Device Review. Inside you will find the following: - Revenue performance of key public companies, as well as peripheral vascular M&A and investments through 2022 - FSI’s view of key trends from leading companies in the PV space and those investing in peripheral vascular - devices - Analysis of VC investments in select PV device segments, as well as M&A activity and IPOs

This report highlights FSI's Cardiovascular Device Review of 2022. Inside you will find the following: - Revenue performance of key public companies, as well as cardiovascular M&A and investments through 2022  - FSI’s view of key trends from leading cardiovascular device companies and those investing in cardiovascular devices   - Analysis of VC investments in select cardiovascular device segments, as well as M&A activity and IPOs

This report highlights performance of the Digital Health segment in the first half of 2022 as compared to previous years, as well as investments and exits. Included are public company revenue performance in key segments such as Telehealth and Healthcare IT, as well as analyses of Digital Health VC investments, M&A, and IPOs.

This report provides a review of revenue performance of public companies in FSI’s Digital Health segments in 2022 as compared to previous years. Inside you will find FSI’s view of key trends from leading Digital Health companies and those investing in Digital Health (Medtech, the Big Four Tech, and Payors), as well as analysis of Digital Health VC investments, M&A, and IPOs

This report provides a review of revenue growth for public companies in FSI’s Medtech segments in H2 2022 as well as US Medtech investments and exits

Microbiome Consumables and Services Pulmonary Testing Clinical Research Organization Sleep Apnea Device Oncology CRO Pharma Clinical Trial Logistics Academic Medical Center Pharma Commercialization Services Digital Health Staffing Solution Clinical Research Organization Heath System Innovation Group Academic Medical Center Women's Health Novel Surgical Device Diligence Home Care Digital Health Solution

This report highlights the analysis of the Robotic Assisted Surgery (RAS) Landscape in 2022. Inside you will find the following: - FSI’s unique framework used to analyze 128 RAS platforms - Product development stage and funding status of 110 RAS companies - Key trends from medtech executives and hospital perspective along with challenges and opportunities for companies and investors - Analysis of VC investments and M&A in RAS

FSI's views on investments in the DCT space, regulatory trends, and applicability by therapeutic area shed light on how this emerging approach to clinical development will be adopted by industry.